OBJECTIVE: To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). MATERIALS AND METHODS: Mexican women were interviewed, and blood and urine samples were collected from them (cases/controls= 197/220). The concentration of urinary arsenic species and the polymorphisms of interest were determined by high-performance liquid chromatography with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) and polymerase chain reaction (PCR), respectively. RESULTS: In women with a high %MMA (urinary monomethyl arsenic) and high primary methylation ratio (PM = MMA/iAs), the risk of BC was increased (odds ratio [OR]%MMA T3 vs.T1= 3.60: 95% confidence interval [CI] 2.02-6.41, ORPMI T3 vs.T1= 3.47: 95%CI 1.95-6.17), which was maintained after adjusting for polymorphisms. No significant interactions were observed between the polymorphisms and the arsenic variables on the risk of BC. CONCLUSION: Pro 12Ala and Ala203Pro polymorphisms did not modify the association between the iAs methylation capacity and BC.
OBJECTIVE: To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). MATERIALS AND METHODS: Mexican women were interviewed, and blood and urine samples were collected from them (cases/controls= 197/220). The concentration of urinary arsenic species and the polymorphisms of interest were determined by high-performance liquid chromatography with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) and polymerase chain reaction (PCR), respectively. RESULTS: In women with a high %MMA (urinary monomethyl arsenic) and high primary methylation ratio (PM = MMA/iAs), the risk of BC was increased (odds ratio [OR]%MMA T3 vs.T1= 3.60: 95% confidence interval [CI] 2.02-6.41, ORPMI T3 vs.T1= 3.47: 95%CI 1.95-6.17), which was maintained after adjusting for polymorphisms. No significant interactions were observed between the polymorphisms and the arsenic variables on the risk of BC. CONCLUSION:Pro 12Ala and Ala203Pro polymorphisms did not modify the association between the iAs methylation capacity and BC.
Authors: Gladis Michel-Ramirez; Rogelio Recio-Vega; R Clark Lantz; A Jay Gandolfi; Edgar Olivas-Calderon; Binh T Chau; Mary Kay Amistadi Journal: J Appl Toxicol Date: 2019-10-21 Impact factor: 3.446
Authors: Katie M O'Brien; Alexandra J White; Dale P Sandler; Brian P Jackson; Margaret R Karagas; Clarice R Weinberg Journal: Epidemiology Date: 2019-01 Impact factor: 4.822
Authors: Wojciech Marciniak; Róża Derkacz; Magdalena Muszyńska; Piotr Baszuk; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Anna Jakubowska; Michał Falco; Tadeusz Dębniak; Marcin Lener; Oleg Oszurek; Katherine Pullella; Joanne Kotsopoulos; Ping Sun; Steven A Narod; Jan Lubiński Journal: Int J Cancer Date: 2019-08-26 Impact factor: 7.396